Anti-viral T cell responses in patients with chronic HCV infection treated with telaprevir: can therapy induce functional T cell reconstitution? [Risposte T-linfocitarie HCV-specifiche in pazienti con epatite cronica C trattati con Telaprevir: la funzione anti-virale linfocitaria può essere ripristinata dalla terapia?]

Trial Profile

Anti-viral T cell responses in patients with chronic HCV infection treated with telaprevir: can therapy induce functional T cell reconstitution? [Risposte T-linfocitarie HCV-specifiche in pazienti con epatite cronica C trattati con Telaprevir: la funzione anti-virale linfocitaria può essere ripristinata dalla terapia?]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacodynamics
  • Most Recent Events

    • 02 Mar 2016 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
    • 04 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top